Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy.
about
Gene therapy on the moveCell-based interventions in utero: time to reconsiderLentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.Gene therapy for inherited immunodeficiency.Mouse transplant models for evaluating the oncogenic risk of a self-inactivating XSCID lentiviral vectorCenter for fetal monkey gene transfer for heart, lung, and blood diseases: an NHLBI resource for the gene therapy community.Long-term in vivo monitoring of mouse and human hematopoietic stem cell engraftment with a human positron emission tomography reporter gene.Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy.Development of gene therapy for blood disorders: an update.Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.No impact of lentiviral transduction on hematopoietic stem/progenitor cell telomere length or gene expression in the rhesus macaque model.Lentiviral vectors for the treatment of primary immunodeficiencies.Evidence for the in vivo safety of insulated foamy viral vectorsPerspective on innovative therapies for globoid cell leukodystrophy.Genome editing technologies: defining a path to clinic.Ex vivo and in vivo genome editing: a regulatory scientific framework from early development to clinical implementation.Technical considerations for the generation of novel pseudotyped viruses
P2860
Q27007012-BFBA7D94-7969-4A7E-9122-10FE2B21DBB5Q34198128-BDFE35F2-1712-43B3-AF63-D0039F3CEDEAQ34356904-BA9C1206-3F3B-4FD5-87BC-A47E64312CA6Q34419791-7D8933EA-120B-4173-AEE9-4DA1D84DBCCBQ34692989-804FF07A-E378-4EB1-AC7E-1610C6BC5188Q36401337-5529F5D2-A994-47C7-AADC-622F28509C6DQ36583196-322C654C-3FE5-4E8B-8F11-F40365E967EBQ36698269-229F3A7F-7D6C-407E-B3FC-86A62D1B38FCQ37132611-56D5E464-2FC6-4E18-BA52-7A2C2FEAEAE8Q37620826-095CD821-637B-4323-A40E-D396099921E3Q37690474-17E9C19B-2CB9-4084-961E-9E3067261DBFQ38195200-62D42761-B2F9-4D07-A4B8-29784639C1B0Q38724310-FACF8E6A-EE12-4483-AD35-BFD06598875BQ38957277-4392098C-2754-427B-BA43-75D2CF8F3168Q42560365-1C427762-791A-43F8-9E3D-50C3EBBA2DFFQ48529117-FA79ABAB-6E2C-4AFC-9604-28D07436B2A1Q57275154-AD487FCE-7135-4E5E-8841-383F95FB1133
P2860
Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Challenges in vector and trial ...... oietic stem cell gene therapy.
@en
Challenges in vector and trial ...... oietic stem cell gene therapy.
@nl
type
label
Challenges in vector and trial ...... oietic stem cell gene therapy.
@en
Challenges in vector and trial ...... oietic stem cell gene therapy.
@nl
prefLabel
Challenges in vector and trial ...... oietic stem cell gene therapy.
@en
Challenges in vector and trial ...... oietic stem cell gene therapy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Challenges in vector and trial ...... oietic stem cell gene therapy.
@en
P2093
Brian P Sorrentino
Christopher Baum
Eugene Rosenthal
Gösta Gahrton
Hans-Peter Kiem
Jacqueline Corrigan-Curay
Linda Wolff
Marina O'Reilly
P2860
P304
P356
10.1038/MT.2012.93
P50
P577
2012-06-01T00:00:00Z